Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer

Blog Article

Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte.CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains.Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation.CAR T cell therapy has revolutionized the treatment of hematologic malignancies.

Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success.Here we review the challenges in achieving effective CAR T markbroyard.com cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC).A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens.They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1).

Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine beetroot birkenstock kinase 7 (PTK7) are currently under investigation in clinical trials.The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed.Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene.